Developing treatments for the diseases that are hardest to treat*
We wholly own a platform with the potential for treating a wide range of diseases — from cancers to inflammation-based diseases like arthritis and kidney disease. Endocyte technology is in late-stage clinical trials and is under review for conditional approval in Europe.
PLATFORM YIELDS MULTIPLE NEW SMDCs*
|PROGRAM / INDICATION||PHASE||DISCOVERY||PRECLINICAL||PHASE 1||PHASE 2||PHASE 3||PENDING
|ONCOLOGY – FOLATE RECEPTOR|
|Platinum Resistant Ovarian Cancer||PENDING APPROVAL|
|Non-small Cell Lung Cancer||PHASE 2|
|Triple Negative Breast Cancer||PHASE 2|
|Carboplatin/Paclitaxel Combination||PHASE 1|
|Solid Tumors||PHASE 1|
|EC1788 (Folate-DNA alkylator)|
|Folate Receptor Positive Tumors||PENDING APPROVAL|
|ONCOLOGY – PROSTATE SPECIFIC MEMBRANE ANTIGEN|
|Prostate Cancer||PHASE 1|
|Prostate Tumors||PHASE 1|
|INFLAMMATION – FOLATE RECEPTOR|
|KIDNEY – FOLATE INHIBITOR|
|EC0371 (Folate-mTor Inhibitor)|
|Polycystic Kidney Disease||PRECLINICAL|
SMDC Companion Imaging Diagnostic
Endocyte technology has the potential for broad application
Our technology has the potential to treat the types of cancers found in over 40% of cancer patients worldwide.1 Our lead companion imaging agent and SMDC target the folate receptor, which is frequently expressed in some of the most prevalent, and difficult to treat, solid tumor cancer indications, including non-small cell lung, breast, colorectal, kidney, endometrial, and ovarian cancers.
Using our flexible SMDC technology platform, we are also developing precision therapies for other cancer-cell receptors and diseases. One of our imaging agents, EC0652, is being developed to non-invasively identify tumors that overexpress prostate-specific membrane antigen (PSMA) receptors, and is currently being evaluated in a Phase 1 trial for patients with advanced prostate cancer.
An engine for new drug development
With the advent of an innovative form of delivery, more research and development can focus on new potent cytotoxic drugs.
What’s more, our modular technology is being studied with different drugs or a combination of drugs in a variety of diseases, allowing for potential expansion into lower-expressing cancer indications and other difficult-to-treat diseases.
Our pipeline and the future of precision medicine
Three new SMDCs are now entering clinical trials: one is a prostate-specific membrane antigen (PSMA)-targeted drug, another is a candidate for inflammation indication, and the third is designed to deliver a potent chemotherapy drug called tubulysin using our second-generation guidance system.
* The safety and efficacy of these agents have not been established. There is no guarantee that the agents will receive regulatory approval and become commercially available for the uses being investigated.
1. Reference: Low PS, Klaratne SA. Folate-targeted therapeutic and imaging agents for cancer. Curr Opin Chem Biol. 2009 Jun;13(3):256-262. doi: 10.1016/j.cbpa.2009.03.022. Epub 2009 May 4.